Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nedosiran sodium by Novo Nordisk for Primary Hyperoxaluria Type II: Likelihood of Approval
Nedosiran sodium is under clinical development by Novo Nordisk and currently in Phase III for Primary Hyperoxaluria Type II. According...
Nedosiran sodium by Novo Nordisk for Primary Hyperoxaluria: Likelihood of Approval
Nedosiran sodium is under clinical development by Novo Nordisk and currently in Phase I for Primary Hyperoxaluria. According to GlobalData,...
NNC0519-0130 by Novo Nordisk for Obesity: Likelihood of Approval
NNC0519-0130 is under clinical development by Novo Nordisk and currently in Phase II for Obesity. According to GlobalData, Phase II...
NNC0519-0130 by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
NNC0519-0130 is under clinical development by Novo Nordisk and currently in Phase II for Type 2 Diabetes. According to GlobalData,...
Rybelsus by Novo Nordisk for Obesity: Likelihood of Approval
Rybelsus is under clinical development by Novo Nordisk and currently in Phase III for Obesity. According to GlobalData, Phase III...
NN-6491 by Novo Nordisk for Dyslipidemia: Likelihood of Approval
NN-6491 is under clinical development by Novo Nordisk and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I...
NNC-04916075 by Novo Nordisk for Dyslipidemia: Likelihood of Approval
NNC-04916075 is under clinical development by Novo Nordisk and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I...
(Semaglutide + GIP analogue) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
(Semaglutide + GIP analogue) is under clinical development by Novo Nordisk and currently in Phase II for Type 2 Diabetes....
(Dapagliflozin + semaglutide) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
(Dapagliflozin + semaglutide) is under clinical development by Novo Nordisk and currently in Phase I for Type 2 Diabetes. According...
(Cagrilintide + semaglutide) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
(Cagrilintide + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. According...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's (Insulin icodec + Semaglutide)?
(Insulin icodec + Semaglutide) is a recombinant peptide and recombinant protein commercialized by Novo Nordisk, with a leading Phase III...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Denecimig?
Denecimig is a monoclonal antibody commercialized by Novo Nordisk, with a leading Phase III program in Hemophilia A (Factor VIII...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Decitabine + Tetrahydrouridine?
Decitabine + Tetrahydrouridine is a small molecule commercialized by Novo Nordisk, with a leading Phase II program in Sickle Cell...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's NNC0519-0130?
NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program in Type 2 Diabetes. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's HS-001?
HS-001 is a cell therapy commercialized by Novo Nordisk, with a leading Phase II program in Systolic Heart Failure. According...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Tolerogenic DNA?
Tolerogenic DNA is a gene therapy commercialized by Novo Nordisk, with a leading Phase I program in Type 1 Diabetes...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's NN-1845?
NN-1845 is a recombinant protein commercialized by Novo Nordisk, with a leading Phase I program in Type 1 Diabetes (Juvenile...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Cagrisema?
Cagrisema is a recombinant peptide and synthetic peptide commercialized by Novo Nordisk, with a leading Phase III program in Type...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's NN-9932?
NN-9932 is a recombinant peptide commercialized by Novo Nordisk, with a leading Phase III program in Obesity. According to Globaldata,...
NN-9931 by Novo Nordisk for Liver Cirrhosis: Likelihood of Approval
NN-9931 is under clinical development by Novo Nordisk and currently in Phase II for Liver Cirrhosis. According to GlobalData, Phase...